The Texas A&M University System on Tuesday announced a partnership with pharmaceutical giant GlaxoSmithKline to create a $91 million influenza vaccine-manufacturing facility in Bryan-College Station that officials said will generate billions of dollars worth of expenditures per year and will create close to 7,000 jobs.
Gov. Rick Perry headlined the event and said the TAMUS influenza vaccine-manufacturing center will facilitate a rapid national vaccine response.
The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, released its annual analysis of global patent trends today in its fourth-annual State of Innovation report. This publication tracks patent activity across 12 key technology areas using the Thomson Reuters Derwent World Patents Index® (DWPISM) database.
Key findings from the report include:
BD (Becton, Dickinson and Company), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the first drug to be offered in the just-launched BD Simplist™ ready-to-administer, line of prefilled generic injectables. BD Simplist prefilled injectables will be commercialized and manufactured by BD Rx Inc., a wholly-owned subsidiary of BD. The first BD Simplist product BD Rx will launch is Diphenhydramine Hydrochloride Injection, USP, an injectable antihistamine.
Celebrating its 30th anniversary is the Independent Carton Group (ICG), an association of 17 independently owned and operated folding carton companies. During the group's recent general membership meeting in Charleston, SC, several industry professionals were recognized with awards, and the group toured the Kraft paper mill owned by KapStone Paper and Packaging, an ICG vendor since 2002.
X-spine, a global leader in the design and manufacture of devices for the treatment of spinal disease, announces a new USFDA clearance for the Silex sacroiliac (SI) joint fusion system.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and H. Lundbeck A/S announced today that a double-blind, placebo controlled, randomized, multicenter study of Azilect® (rasagiline tablets) met its primary endpoint. The study, known as ANDANTE (Add oN to Dopamine AgoNists in the TrEatment of Parkinson’s disease), assessed the efficacy and tolerability of Azilect as add-on treatment to dopamine agonists compared to placebo.
Medical Marijuana Inc. is pleased to inform shareholders that Italy and the Czech Republic have recently legalized marijuana for medicinal use. MJNA will be stepping up its presence and launching its portfolio of products and services, including its revolutionary Cannabidol (CBD) Over-The-Counter (OTC) health and wellness products in Europe, Canada, and the Caribbean Island Nations.
As part of a bold expansion into the $60 billion global drug delivery market, Rainbow BioSciences, the biotech division of Rainbow Coral Corp. (OTCBB: RBCC), today announced it has formed a new partnership to solve the problems posed by systemic drug delivery.
Obagi Medical Products Inc. today announced that it entered into a definitive merger agreement with Valeant Pharmaceuticals International Inc. under which Valeant will acquire all of the outstanding common stock of Obagi for $19.75 per share in cash. The transaction, which values Obagi common stock at approximately $360 million, was unanimously approved by the Obagi Board of Directors.